Kidney Week

Abstract: FR-OR093

Global, Regional, and National Burden of CKD in Adults: Updated Systematic Analyses of the Global Burden of Disease Study

Session Information

• Late-Breaking Research Orals - 2
  November 07, 2025 | Location: Grand Ballroom C, Convention Center
  Abstract Time: 05:30 PM - 05:42 PM

Category: CKD (Non-Dialysis)

• 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

• Mark, Patrick Barry, University of Glasgow, Glasgow, Scotland, United Kingdom

Patrick Barry Mark, MBChB, PhD

• Stafford, Lauryn K, University of Washington, Seattle, Washington, United States

Lauryn K Stafford, MS

• Grams, Morgan, New York University Grossman School of Medicine, New York, New York, United States

Morgan Grams, MD, PhD

• Lees, Jennifer S., University of Glasgow, Glasgow, Scotland, United Kingdom

Jennifer S. Lees, MA, MBChB, PhD

• Ong, Kanyin Liane, University of Washington, Seattle, Washington, United States

Kanyin Liane Ong, PhD

• Coresh, Josef, New York University Grossman School of Medicine, New York, New York, United States

Josef Coresh, MD, PhD, FASN

Group or Team Name

• CKD-GBD Collaborators.

Background

Chronic kidney disease (CKD) ranks among leading causes of mortality and morbidity. We present updated CKD estimates from the most recent Global Burden of Disease 2023 study to inform policy for CKD identification and treatment.

Methods

We focus on adults age >20 years over 1990-2023. Data sources used were published literature, vital registration systems, renal registries, and household surveys. Estimates of CKD burden, including deaths, incidence, prevalence, and disability-adjusted life-years (DALYs), were produced. Comparative risk assessments estimated proportion of cardiovascular deaths attributable to impaired kidney function and estimate the risk factors for CKD.

Results

Globally, 788 million (95% uncertainty interval 743–843) people were estimated to have CKD, up from 378 million (354–407) in 1990. Global age-standardised prevalence of CKD was 14.2% (13.4–15.2), a relative rise of 3.5% (2.7–4.1) from 1990. The region with highest age-standardised prevalence was north Africa and the Middle East (18.0%; 16.9–19.4). Most people had stage 1-3 CKD, with a combined prevalence of 13.9% (13.1–15.0). CKD was the 9th leading cause of death globally, accounting for 1.48 million (1.30–1.65) deaths, and CKD was the 12th leading cause of DALYs with age-standardised DALY rate of 769.2 per 100,000 (691.8–857.4)(see Figure). Impaired kidney function as a risk factor accounted for 11.5% (8.4–14.6) of cardiovascular deaths. Elevated plasma glucose, body-mass index, and systolic blood pressure were the leading risk factors for CKD associated DALYs.

Conclusion

The prevalence of CKD continues to rise. CKD increases its importance as a cause of death (now ranking 9^th for deaths and 12^th for DALYs globally) and as a risk factor for cardiovascular death, increasing the urgency for translating advances in CKD treatment into improved prevention and treatment.

Rank of CKD amongst leading causes of death, DALYs and as risk factor for cardiovascular death

Funding

• NIDDK Support

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.2025dzpbxjpn